# Crescent Biopharma, Inc. (CBIO)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $484M  
**Price:** $17.57 (-2.39%)

> Crescent Biopharma, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies in the pharmaceutical sector. It specializes in advancing treatments that address significant unmet medical needs, often targeting niche or rare diseases. The company’s pipeline and research efforts aim to bring novel drug candidates through clinical development stages to improve patient outcomes. Crescent Biopharma plays a role in the broader healthcare and life sciences industry by contributing to medical innovation and therapeutic advancements. Its presence in financial markets, including listing on the Frankfurt Stock Exchange, allows investors to track its progress and financial performance as it works toward enhancing treatment options in biomedicine.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $11M | — | -$153M | -$154M | — |
| 2023 | $10,000 | — | -$39M | -$37M | — |
| 2022 | $75,000 | — | -$47M | -$47M | — |
| 2021 | $1M | — | -$63M | -$63M | — |
| 2020 | $10M | — | -$52M | -$51M | — |
| 2016 | $18,500 | — | -$32M | -$32M | — |
| 2015 | $20M | — | -$13M | -$13M | — |
| 2014 | $15M | — | -$11M | -$11M | — |
| 2013 | $4M | — | -$11M | -$11M | — |
| 2012 | $15M | — | $4M | $4M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $240M | $37M | $203M | $213M | — |
| 2023 | $45M | $7M | $38M | $42M | — |
| 2022 | $52M | $9M | $43M | $48M | — |
| 2021 | $94M | $13M | $82M | $90M | — |
| 2020 | $143M | $15M | $128M | $137M | — |
| 2016 | $42M | $7M | $35M | $40M | — |
| 2015 | $48M | $8M | $40M | $47M | — |
| 2014 | $57M | $6M | $51M | $55M | — |
| 2013 | $5M | $2M | $3M | $2M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$72M | $919,000 | -$72M |
| 2024 | -$31M | $9,972 | -$31M |
| 2023 | -$35M | $21,394 | -$35M |
| 2022 | -$46M | $84,191 | -$47M |
| 2021 | -$57M | $14,943 | -$58M |
| 2020 | -$39M | $68,507 | -$39M |
| 2019 | -$52M | $144,928 | -$52M |
| 2018 | -$43M | $125,618 | -$43M |
| 2017 | -$30M | $294,107 | -$30M |
| 2016 | -$30M | $704,202 | -$30M |
| 2015 | -$8M | $268,594 | -$9M |

Source: [CompaniesByCap](https://companiesbycap.com/company/CBIO)